| Whole MS no = 65 | MS relapsing-remitting no = 35 | MS secondary progressive no = 20 | MS primary progressive no = 10 | |
| Age (years) | 41 (34 to 48) | 35 (29 to 41) | 45 (42 to 52) | 58 (46 to 60) |
| Sex: percentage male, male/female | 46%, 30/35 | 46%, 16/19 | 45%, 9/11 | 50%, 5/5 |
| EDSS | 2.5 (1 to 5) | 1.5 (0.5 to 2) | 5 (3.5 to 6.5) | 4.3 (3 to 6.5) |
| Disease duration (years) | 6 (3 to 13) | 4 (1 to 7) | 13 (6 to 21) | 10 (5 to 14) |
| HLA2 (DR15) haplotype carriers (C)+%+/tot | 54% 15/28 | 71% 10/14 | 27% 3/11 | 67% 2/3 |
| Cerebrospinal fluid oligoclonal bands+%+/tot | 91% 40/44 | 86% 19/22 | 100% 17/17 | 80% 4/5 |
| Compliance with at least three of four MRI revised McDonald criteria%+/tot | 100% 65/65 | 100% 35/35 | 100% 20/20 | 100% 10/10 |
No significant differences were found among MS subgroups for age, expanded disability disease score (EDSS), or disease duration (ANOVA). HLA2 (DR15) genetic analysis was available in 28/65 patients, and cerebrospinal fluid in 44/65.